Tempus AI, Inc. , a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025.

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Improve AI model performance for lung cancer diagnostics: Leverage Tempus' real-world data to continuously refine Imagene's lung AI models, ensuring cutting-edge accuracy and effectiveness in ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

Zwift has partnered with Sir Chris Hoy's Tour de 4 initiative to help raise money for cancer charities across the UK. The ...

James William Rogers (NYSE:ROG), the Chief Financial Officer of Tempus AI , Inc. (NASDAQ:TEM), recently sold 8,712 shares of the company’s Class A common stock. The shares were sold at a weighted ...

Andrew Polovin, the Executive Vice President and General Counsel of Tempus AI , Inc. (NASDAQ:TEM), a company currently valued at $10.2 billion, recently executed a stock sale as part of a pre-arranged ...

Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.